p-n-Nonylphenoxydecaethoxyethanol | 20543-07-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-n-Nonylphenoxydecaethoxyethanol
• 英文别名: 32-(4-Nonylphenoxy)-3,6,9,12,15,18,21,24,27,30-decaoxadotriacontan-1-ol；2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
• CAS: 20543-07-1
• 化学式: C₃₇H₆₈O₁₂
• 分子量: 704.94
• InChiKey: YFTZKLGVTSRCMS-UHFFFAOYSA-N

物化性质

• 沸点：
  716.7±60.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  49
• 可旋转键数：
  41
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  12

文献信息

• Method of modulating stress-activated protein kinase system
  申请人：Blatt M. Lawrence

  公开号：US20060270612A1

  公开（公告）日：2006-11-30

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  本发明涉及使用活性化合物调节应激激活蛋白激酶（SAPK）系统的方法，该活性化合物对至少一种p38 MAPK的抑制作用具有低效性；并且所述接触是在低百分比抑制浓度下进行的SAPK调节浓度，以抑制化合物对至少一种p38 MAPK的作用。此外，本发明还涉及吡非酮的衍生物，这些衍生物可以调节SAPK系统。
• Piperazine and piperidine biaryl derivatives
  申请人：Lu Jian Rong

  公开号：US20070259879A1

  公开（公告）日：2007-11-08

  This invention relates to piperazine and piperidine biaryl compounds of Formula (I): or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative thereof; and to processes for preparing the compounds or pharmaceutical compositions containing the same. The compounds and pharmaceutical compositions of the present invention are provided for use in the treatment of HIV infection and/or AIDS.

  本发明涉及公式（I）的哌嗪和哌啶双芳基化合物： 或其药物可接受的前药、盐、多晶形、溶剂化物、对映体、非对映体、外消旋体、其立体异构体混合物或衍生物；以及用于制备化合物或含有相同化合物的制药组合物的过程。本发明的化合物和制剂用于治疗HIV感染和/或艾滋病。
• METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
  申请人：Blatt Lawrence M.

  公开号：US20120258924A1

  公开（公告）日：2012-10-11

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  本发明涉及使用活性化合物调节应激激活蛋白激酶（SAPK）系统的方法，其中该活性化合物对至少一种p38 MAPK抑制的效力较低；并且该接触是在该化合物对至少一种p38 MAPK的抑制浓度低百分比的SAPK调节浓度下进行的。本发明还涉及吡非尼酮的衍生物，这些衍生物可以调节应激激活蛋白激酶（SAPK）系统。
• Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
  申请人：Intermune, Inc.

  公开号：EP2591784A1

  公开（公告）日：2013-05-15

  Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

  公开了用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物对抑制至少一种p38 MAPK表现出较低的效力；并且接触是在SAPK调节浓度下进行的，该浓度是化合物抑制至少一种p38 MAPK的低百分比抑制浓度。还公开了吡非尼酮的衍生物。这些衍生物可以调节应激活化蛋白激酶（SAPK）系统。
• Peptoids and methods for treating Alzheimer's disease
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS

  公开号：US10167315B2

  公开（公告）日：2019-01-01

  Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least four monomers with a side-chain having an arylalkyl or aryl group. The peptoid may be achiral. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.

  本文提供的蛋白胨能够抑制或逆转淀粉样β（Aβ）纤维或斑块的产生。类蛋白胨形成螺旋结构，每螺旋转折处有三个单体，并且至少有四个单体的侧链具有芳基烷基或芳基。蛋白胨可以是非手性的。此外，还提供了使用类蛋白胨抑制或逆转 Aβ 聚集的方法，以及治疗阿尔茨海默病（AD）患者或延缓 AD 进展的方法。